Role of the 5-Lipoxygenase Pathway in Atherosclerosis

5-脂氧合酶途径在动脉粥样硬化中的作用

基本信息

  • 批准号:
    7452453
  • 负责人:
  • 金额:
    $ 49.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-15 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): 1 strategy for identifying novel atherosclerosis-related genes and pathways is through a combination of studies using mouse models and human populations. Using this approach, we recently identified 5-lipoxygenase (5-LO), the rate-limiting enzyme in leukotriene (LT) biosynthesis, as a gene with dramatic effects on atherosclerosis susceptibility in mice and humans. The role of LT metabolism in the development of other allergic inflammatory diseases, most notably asthma, is already well known. This proposal, however, will address several fundamental questions that remain to be answered regarding the role of this pathway in coronary artery disease (CAD). The first aim will determine whether polymorphisms in the major genes of the 5-LO/LT pathway are associated with atherosclerosis using a large cohort of approximately 5,000 individuals on whom the diagnosis of CAD has been definitively assessed by angiography. This will not only confirm the initial observations with 5-LO, but will also determine whether genetic variation in other LT biosynthesis genes are also important for atherogenesis. The second aim will biochemically characterize the genes and polymorphisms that statistical associations in the first aim have been observed with. To complement these 2 approaches, the third aim focuses on creating additional knock out mouse models for other pathway genes. These mice will allow the genetic dissection of the pathway and the testing of specific hypotheses regarding the patho-physiological mechanism by which LTs increase atherosclerosis. 1 of the long term goals of this project are to develop genetic diagnostic tests that could be used to help identify persons at an increased risk for CAD, much in the same way that traditional risk factors, such as elevated LDL or blood pressure, are presently being used. If the 5-LO/LT pathway proves to be important for CAD, 1 of the most promising benefits could be the application of already existing drugs currently used for asthma to the management of CAD, which could lead to newer and more effective therapies.
描述(由申请人提供):1通过使用小鼠模型和人群的研究组合,确定新的动脉粥样硬化相关基因和途径的策略。使用这种方法,我们最近确定了5-脂氧合酶(5-LO),在白三烯(LT)的生物合成的限速酶,作为一个基因与动脉粥样硬化的易感性在小鼠和人类的显着影响。LT代谢在其他过敏性炎症性疾病(最显著的是哮喘)发展中的作用已经众所周知。然而,这项提议将解决几个关于该途径在冠状动脉疾病(CAD)中的作用仍有待回答的基本问题。第一个目标是确定5-LO/LT通路主要基因的多态性是否与动脉粥样硬化相关,使用约5,000名通过血管造影明确诊断CAD的个体的大型队列。这不仅将证实5-LO的初步观察结果,而且还将确定其他LT生物合成基因的遗传变异是否对动脉粥样硬化形成也很重要。第二个目标将对第一个目标中观察到的统计关联的基因和多态性进行生物化学表征。为了补充这两种方法,第三个目标重点是为其他途径基因创建额外的敲除小鼠模型。这些小鼠将允许对该途径进行遗传解剖,并测试关于LT增加动脉粥样硬化的病理生理机制的特定假设。该项目的长期目标之一是开发可用于帮助识别CAD风险增加的人的遗传诊断测试,与目前使用的传统风险因素(如LDL升高或血压)大致相同。如果5-LO/LT通路被证明对CAD很重要,那么最有希望的益处之一可能是将目前用于哮喘的现有药物应用于CAD的管理,这可能导致更新和更有效的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hooman Allayee其他文献

Hooman Allayee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hooman Allayee', 18)}}的其他基金

Biological Mechanisms through which TMAO Promotes Atherosclerosis
TMAO促进动脉粥样硬化的生物学机制
  • 批准号:
    10368090
  • 财政年份:
    2020
  • 资助金额:
    $ 49.48万
  • 项目类别:
Biological Mechanisms through which TMAO Promotes Atherosclerosis
TMAO促进动脉粥样硬化的生物学机制
  • 批准号:
    10592245
  • 财政年份:
    2020
  • 资助金额:
    $ 49.48万
  • 项目类别:
Human Translational Bioinformatics Core
人类转化生物信息学核心
  • 批准号:
    10713763
  • 财政年份:
    2018
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of Glycine Metabolism in Cardiovascular Disease
甘氨酸代谢在心血管疾病中的作用
  • 批准号:
    9312093
  • 财政年份:
    2017
  • 资助金额:
    $ 49.48万
  • 项目类别:
Nutrigenetic Intervention to Reduce Liver Fat in Hispanics
减少西班牙裔肝脏脂肪的营养遗传干预
  • 批准号:
    9010742
  • 财政年份:
    2016
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
  • 批准号:
    7836973
  • 财政年份:
    2009
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
  • 批准号:
    7643266
  • 财政年份:
    2005
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
  • 批准号:
    6986373
  • 财政年份:
    2005
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
  • 批准号:
    7279132
  • 财政年份:
    2005
  • 资助金额:
    $ 49.48万
  • 项目类别:
Role of the 5-Lipoxygenase Pathway in Atherosclerosis
5-脂氧合酶途径在动脉粥样硬化中的作用
  • 批准号:
    7112247
  • 财政年份:
    2005
  • 资助金额:
    $ 49.48万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 49.48万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 49.48万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 49.48万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 49.48万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 49.48万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 49.48万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 49.48万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 49.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 49.48万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 49.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了